J&J CFO Caruso Breaks Down the Earnings Numbers

The transcript features an interview with Johnson & Johnson's CFO, Dominic Caruso, discussing the company's strong start to the year, driven by robust pharmaceutical sales and a promising product pipeline. The conversation covers the potential impact of biosimilars on Remicade, the company's capital allocation strategy, including dividends and share buybacks, and the performance of the consumer business in emerging markets. Caruso also addresses the topic of corporate tax inversions, emphasizing the need for tax system reform to encourage innovation.

What is the main reason the company is not expecting a biosimilar competitor for Remicade in 2016?

• High production costs

• Regulatory hurdles

• Lack of market demand

• Strong intellectual property protection

How many new pharmaceutical products is the company planning to file between now and 2019?

• 10

• 15

• 20

• 5

What is the company's primary strategy for handling excess cash?

• Expanding into new markets

• Share buybacks and dividends

• Investing in new technologies

• Increasing employee salaries

In which markets is the consumer business seeing significant opportunities despite economic slowdowns?

• North American markets

• European markets

• Emerging markets

• Developed markets

What is the main topic of discussion regarding corporate tax inversions?

• The benefits of higher tax rates

• The need for a revised corporate tax system

• The role of international trade agreements

• The impact on small businesses